The results of complex treatment of patients with inflammatory bowel diseases using 5-aminosalicylic acid (5-ASA) drugs, corticosteroids, immunosuppressants and biological therapy

Introduction: In the absence of a positive response during treatment with 5-ASA drugs and hormones, reserve drugs - immunosuppressant’s are prescribed, which in some cases does not solve the problem of treating refractory forms of Ulcerative colitis (UC) and Crohn`s disease (CD). In addition, the use of immunosuppressant’s in certain least limited to a wide range of side effects characteristic of cytostatic. The development of refractoriness to treatment is observed on average in 35–40% of patients and leads to severe complications, surgical interventions and disability of young people working age. Currently, in the complex treatment of this category of patients using "biological" drugs. The biological method is based on concept of the leading role of proinflammatory cytokines in the pathogenesis of intestinal inflammation and the possible blockade of their biological effects by anti-inflammatory cytokines. Quite effective and safe with refractory clinical inflammatory bowel disease, is infliximab. Methods: We study used infliximab for treatment of patients with inflammatory bowel diseases in complex therapy with 5-ASA drugs, corticosteroids and immunosuppressants: 15 patients with UC and 5 patients with CD